US price of Praluent slashed by 60%

11 February 2019

Joining in what looks set to be a price war for biotech drugs called PCSK9 inhibitors for the treatment of bad cholesterol, USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) and partner French pharma major Sanofi (Euronext SAN) today announced a further reductions of their partnered product.

Praluent (alirocumab) will be made available at a new reduced US list price of $5,850 annually, a 60% reduction from the original price, for both the 75mg and 150mg doses, beginning in early March.

This follows on the news that rival PCSK9 inhibitor Repatha (evolocumab) from Amgen (Nasdaq: AMGN) has its price cut by 60% last October.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK